Literature DB >> 11397142

An immunotherapeutic program for the treatment of nicotine addiction: hapten design and synthesis.

S Isomura1, P Wirsching, K D Janda.   

Abstract

People continue to smoke and use tobacco products despite well-established hazardous consequences. The most contributing factor is the addictive nature of nicotine. There is no highly effective treatment for the problem of nicotine dependence. Immunotherapy offers an alternative to conventional approaches. The chemistry necessary for a comprehensive immunopharmacological program is presented. Haptens for the generation of antibodies specific for naturally occurring (S)-nicotine, (S)- and (R)-nornicotine, and the metabolite (S)-cotinine were prepared with high optical purity. Preliminary data for antinicotine antibodies are reported.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11397142     DOI: 10.1021/jo001442w

Source DB:  PubMed          Journal:  J Org Chem        ISSN: 0022-3263            Impact factor:   4.354


  18 in total

1.  A previously undescribed chemical link between smoking and metabolic disease.

Authors:  Tobin J Dickerson; Kim D Janda
Journal:  Proc Natl Acad Sci U S A       Date:  2002-10-28       Impact factor: 11.205

Review 2.  Conjugate Vaccine Immunotherapy for Substance Use Disorder.

Authors:  Paul T Bremer; Kim D Janda
Journal:  Pharmacol Rev       Date:  2017-07       Impact factor: 25.468

Review 3.  Vaccines against drugs of abuse: where are we now?

Authors:  Berma Kinsey
Journal:  Ther Adv Vaccines       Date:  2014-07

4.  AAV-directed persistent expression of a gene encoding anti-nicotine antibody for smoking cessation.

Authors:  Martin J Hicks; Jonathan B Rosenberg; Bishnu P De; Odelya E Pagovich; Colin N Young; Jian-ping Qiu; Stephen M Kaminsky; Neil R Hackett; Stefan Worgall; Kim D Janda; Robin L Davisson; Ronald G Crystal
Journal:  Sci Transl Med       Date:  2012-06-27       Impact factor: 17.956

5.  Structurally distinct nicotine immunogens elicit antibodies with non-overlapping specificities.

Authors:  M Pravetoni; D E Keyler; R R Pidaparthi; F I Carroll; S P Runyon; M P Murtaugh; C A Earley; P R Pentel
Journal:  Biochem Pharmacol       Date:  2011-11-15       Impact factor: 5.858

6.  Scientific overview: 2013 BBC plenary symposium on tobacco addiction.

Authors:  M De Biasi; I McLaughlin; E E Perez; P A Crooks; L P Dwoskin; M T Bardo; P R Pentel; D Hatsukami
Journal:  Drug Alcohol Depend       Date:  2014-06-02       Impact factor: 4.492

Review 7.  Immunopharmacotherapy: vaccination strategies as a treatment for drug abuse and dependence.

Authors:  Amira Y Moreno; Kim D Janda
Journal:  Pharmacol Biochem Behav       Date:  2009-04       Impact factor: 3.533

8.  Drugs of abuse that mediate advanced glycation end product formation: a chemical link to disease pathology.

Authors:  Jennifer B Treweek; Tobin J Dickerson; Kim D Janda
Journal:  Acc Chem Res       Date:  2009-05-19       Impact factor: 22.384

9.  Enhancing nicotine vaccine immunogenicity with liposomes.

Authors:  Jonathan W Lockner; Sam On Ho; Karen C McCague; Su Ming Chiang; Thai Q Do; Gary Fujii; Kim D Janda
Journal:  Bioorg Med Chem Lett       Date:  2012-12-27       Impact factor: 2.823

Review 10.  Advances in smoking cessation pharmacotherapy: Non-nicotinic approaches in animal models.

Authors:  Lauren C Smith; Olivier George
Journal:  Neuropharmacology       Date:  2020-08-03       Impact factor: 5.250

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.